

New Research into Prescribing Practices

<https://marketpublishers.com/r/N1EB5441CEEEN.html>

Date: August 2011

Pages: 43

Price: US\$ 695.00 (Single User License)

ID: N1EB5441CEEEN

Abstracts

Every day, doctors make hundreds of decisions. Decisions that affect patient care, diagnosis, follow up and pharmaceuticals prescribed.

What influences those choices? When it comes to prescribing habits, says Dr G Caleb Alexander, a University of Chicago assistant professor of medicine, “this is one of the great unknowns. It’s pretty tough to accurately identify the sources and magnitude of influence that guides physician learning.”

Yet comparative effectiveness research (CER) in the US is not only shedding light on comparing disease treatments, but prompting detailed examinations of how doctors make prescribing decisions and the factors that sway them.

Report Overview

In New Research into Prescribing Practices, FirstWord reviews the role of CER intelligence, the significant gaps it has identified in physician knowledge and how CER information will shape the way that pharmaceutical firms promote their products. Based on expert interviews and the latest research, the report reveals the key factors influencing physician decisions, from formal education, casual colleague conversations, insurance regulations and government subsidies to continuing medical education, samples and even patient pressure.

Key features

Compelling insight into how pharma can address prescribing trends

Examination of CERs influence on pharma, patient care and academic detailing

Expert insight into how new drug promotions can evolve

Discussion of how promotions can impact doctor-patient relations

Analysis of why some drugs are overprescribed while others are underutilized

Charts and tables illustrating compliance, prescribing trends

Purchase Reasons

Expert advice on how pharma and CER projects can influence physician choice

Insight into the dominant factors affecting prescribing habits

Key Questions Asked

How can pharma identify which doctors respond to which promotional techniques?

What are the key factors affecting how doctors prescribe pharmaceuticals according to CER research?

How do promotional emphases need to change over the life cycle of a new drug?

How can pharma firms build goodwill by helping doctor-patient communication?

How are CER projects informing how pharma firms market their products?

What are the gaps in physician knowledge?

Who Should Read This Report

Marketing and Brand Management

Advertising/Promotion

Medical Education

Marketing Research/Business Intelligence

Sales Management

Territory Management/Sales Representatives

Key quotes

“Armed with this comparative information, doctors and patients can discuss the pros and cons of medications to come up with one that best fits the patient’s needs and preferences.”

– Dr Carolyn M Clancy, director of AHRQ

CER is “the next stage in an evolution of research and knowledge development in regard to medical intervention... Embracing CER is regarded as an essential step for the innovative pharmaceutical industry.”

– Marc L Berger, vice-president of global health outcomes and David Grainger, global public policy director, Eli Lilly

“It’s pretty tough to accurately identify the sources and magnitude of influence that guides physician learning. This is one of those great unknowns. We know that some sources are influential, but discussing exactly how influential and in what settings is easier said than done.”

– Dr G Caleb Alexander, assistant professor of medicine, University of Chicago

Expert Views

Dr Carolyn M Clancy, Director, AHRQ

Dr Scott R Smith, Senior Fellow, AHRQ

Dr Ramkumar Janakiraman, Texas A&M University

Dr Ben Gerber, Associate Professor of Medicine, University of Illinois at Chicago

Dr David P Miller, Assistant Professor, Wake Forest University, North Carolina

Dr Julie A Schmittdiel, Research Division, Kaiser Permanente

Dr G Caleb Alexander, Assistant Professor of medicine, University of Chicago

Dr Katherine Y Yang, Assistant Professor at the University of California, San Francisco

Frank Powers, CEO, Dudnyk consultants

Alex Swedlow, Executive Vice-President, Research and Development, California

Workers' Compensation Institute

Contents

EXECUTIVE SUMMARY

COMPARATIVE EFFECTIVENESS RESEARCH

Impact on pharma
Impact on patient care
Academic detailing
Knowing doesn't equal doing

INFLUENCING PHYSICIAN CHOICES

Gaps in physician knowledge
How doctors make their choices
Healthcare coverage
Getting doctors to switch
Custom-tailored detailing
The importance of drug samples

THE ROLE OF PATIENTS

Which promotions work best?
Patient information
Safety considerations
Cost considerations
Combating non-adherence

PERSISTENTLY OVERPRESCRIBED DRUGS

Antibiotics
Opioids

ADDRESSING UNDERPRESCRIBING

Cardiac care
Older patients
Minorities

LOOKING AHEAD

I would like to order

Product name: New Research into Prescribing Practices

Product link: <https://marketpublishers.com/r/N1EB5441CEEEN.html>

Price: US\$ 695.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N1EB5441CEEEN.html>